Biohaven新型肌肉生长抑制素-激活素通路抑制剂Taldefgrobep Alfa二期肥胖研究完成患者入组

美股速递
Mar 19

Biohaven制药控股公司宣布,其针对Taldefgrobep Alfa开展的二期肥胖临床研究已顺利完成患者招募工作。该创新疗法是一种新型肌肉生长抑制素-激活素通路抑制剂,此次研究进展标志着其在代谢疾病治疗领域迈出重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10